EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease

Kam Wa Chan, J David Smeijer, Meir Schechter, Niels Jongs, Priya Vart, Donald E Kohan, Ron T Gansevoort, Adrian Liew, Sydney C W Tang, Christoph Wanner, Dick de Zeeuw, Hiddo J L Heerspink

Kidney International · 2023-12 · 104 (6) · 1219-1226

DOI: 10.1016/j.kint.2023.08.014 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Kidney International, 2023-12. Verfasst von Kam Wa Chan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Division …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie, University of Hong Kong, China Medical Board.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pain is prevalent among patients with diabetes and chronic kidney disease (CKD). The management of chronic pain in these patients is limited by nephrotoxicity of commonly used drugs including non-steroidal anti-inflammatory drugs (NSAIDs) and opioids. Since previous studies implicated endothelin-1 in pain nociception, our post hoc analysis of the SONAR trial assessed the association between the endothelin receptor antagonist atrasentan and pain and prescription of analgesics. SONAR was a randomized, double-blind, placebo-controlled clinical trial that recruited participants with type 2 diabetes and CKD (estimated glomerular filtration rate 25-75 ml/min/1.73 m2; urinary albumin-to-creatinine ratio 300-5000 mg/g). Participants were randomized to receive atrasentan or placebo (1834 each arm). The main outcome was pain-related adverse events (AEs) reported by investigators. We applied Cox regression to assess the effect of atrasentan compared to placebo on the risk of the first reported pain-related AE and, secondly, first prescription of analgesics. We used the Anderson-Gill method to assess effects on all (first and subsequent) pain-related AEs. During 2.2-year median follow-up, 1183 pain-related AEs occurred. Rates for the first pain-related event were 138.2 and 170.2 per 1000 person-years in the atrasentan and placebo group respectively (hazard ratio 0.82 [95% confidence interval 0.72-0.93]). Atrasentan also reduced the rate of all (first and subsequent) pain-related AEs (rate ratio 0.80 [0.70-0.91]). These findings were similar after accounting for competing risk of death (sub-hazard ratio 0.81 [0.71-0.92]). Patients treated with atrasentan initiated fewer analgesics including NSAIDs and opioids compared to placebo during follow-up (hazard ratio = 0.72 [0.60-0.88]). Thus, atrasentan was associated with reduced pain-related events and pain-related use of analgesics in carefully selected patients with type 2 diabetes and CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Renal Insufficiency, ChronicHumansAnti-Inflammatory Agents, Non-SteroidalAtrasentanEndothelin Receptor AntagonistsPainDouble-Blind Method

Stichwörter der Autor:innen

analgesicsatrasentanchronic kidney diseasediabetesnonsteroidal anti-inflammatory drugopioidspain

Substanzen

Anti-Inflammatory Agents, Non-SteroidalAtrasentanEndothelin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Division of Nephrology, Department of Medicine, The University of Hong Kong, Ho…
  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Cen…
  • Division of Nephrology, University of Utah Health, Salt Lake City, Utah, USA.
  • Mount Elizabeth Novena Hospital, Singapore.
  • Division of Nephrology, Department of Medicine, The University of Hong Kong, Hong Kong SAR.

Förderung

  • AbbVie
  • University of Hong Kong
  • China Medical Board

Zitieren

APA

Chan, K. W., Smeijer, J. D., Schechter, M., Jongs, N., Vart, P., Kohan, D. E., Gansevoort, R. T., Liew, A., Tang, S. C. W., Wanner, C., de Zeeuw, D., & Heerspink, H. J. L. (2023). Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease. Kidney International, 104(6), 1219-1226. https://doi.org/10.1016/j.kint.2023.08.014

Vancouver

Chan KW, Smeijer JD, Schechter M, Jongs N, Vart P, Kohan DE, et al. Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease. Kidney International. 2023;104(6):1219-1226. doi:10.1016/j.kint.2023.08.014

BibTeX
@article{Chan2023,
  author = {Chan, Kam Wa and Smeijer, J David and Schechter, Meir and Jongs, Niels and Vart, Priya and Kohan, Donald E and Gansevoort, Ron T and Liew, Adrian and Tang, Sydney C W and Wanner, Christoph and de Zeeuw, Dick and Heerspink, Hiddo J L},
  title = {Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease},
  journal = {Kidney International},
  year = {2023},
  volume = {104},
  number = {6},
  pages = {1219--1226},
  doi = {10.1016/j.kint.2023.08.014}
}
Kostenlos starten →